Comparative efficacy of tenofovir and entecavir in nucleos
To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled tria...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-11, Vol.14 (11), p.e0224773 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | e0224773 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Chen, Mao-bing Wang, Hua Zheng, Qi-han Zheng, Xu-wen Fan, Jin-nuo Ding, Yun-long Niu, Jia-li Kim, Seung Up |
| description | To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis. Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I.sup.2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P |
| doi_str_mv | 10.1371/journal.pone.0224773 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_ISR_A606436399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A606436399</galeid><sourcerecordid>A606436399</sourcerecordid><originalsourceid>FETCH-LOGICAL-g999-4443cd643842501d1eb48fa1f206e58c713a0b7b1acde760314a13a85bc15e583</originalsourceid><addsrcrecordid>eNqFzk1Lw0AQBuBFFKzVf-AhJ8FD4n5lk_VWih-FQkGL1zDZzKYpcbdkk6L_3oge4snTzLw8vAwh14wmTGTsbu-HzkGbHLzDhHIus0yckBnTgseKU3E62c_JRQh7SlORKzUj90v_foAO-uaIEVrbGDCfkbdRj85bf2y6CFwVoevRwPfVuMgNpkUfLsmZhTbg1e-ck-3jw3b5HK83T6vlYh3XWutYSilMpaTIJU8pqxiWMrfALKcK09xkTAAts5KBqTBTVDAJY5SnpWHpCMSc3P7U1tBi0Tjjx18--hqGEIrV60uxUHSsV0Lrf-zm7a-9mdgdQtvvgm-HvvEuTOEXojBn_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative efficacy of tenofovir and entecavir in nucleos</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Chen, Mao-bing ; Wang, Hua ; Zheng, Qi-han ; Zheng, Xu-wen ; Fan, Jin-nuo ; Ding, Yun-long ; Niu, Jia-li ; Kim, Seung Up</creator><creatorcontrib>Chen, Mao-bing ; Wang, Hua ; Zheng, Qi-han ; Zheng, Xu-wen ; Fan, Jin-nuo ; Ding, Yun-long ; Niu, Jia-li ; Kim, Seung Up</creatorcontrib><description>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis. Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I.sup.2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I.sup.2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I.sup.2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I.sup.2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I.sup.2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35]. Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0224773</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Antiretroviral agents ; Carcinoma ; Comparative analysis ; Creatine ; Creatine kinase ; Entecavir ; Hepatitis B ; Hepatitis B virus ; Hepatocellular carcinoma ; Tenofovir</subject><ispartof>PloS one, 2019-11, Vol.14 (11), p.e0224773</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Chen, Mao-bing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zheng, Qi-han</creatorcontrib><creatorcontrib>Zheng, Xu-wen</creatorcontrib><creatorcontrib>Fan, Jin-nuo</creatorcontrib><creatorcontrib>Ding, Yun-long</creatorcontrib><creatorcontrib>Niu, Jia-li</creatorcontrib><creatorcontrib>Kim, Seung Up</creatorcontrib><title>Comparative efficacy of tenofovir and entecavir in nucleos</title><title>PloS one</title><description>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis. Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I.sup.2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I.sup.2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I.sup.2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I.sup.2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I.sup.2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35]. Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</description><subject>Antiretroviral agents</subject><subject>Carcinoma</subject><subject>Comparative analysis</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Entecavir</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatocellular carcinoma</subject><subject>Tenofovir</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFzk1Lw0AQBuBFFKzVf-AhJ8FD4n5lk_VWih-FQkGL1zDZzKYpcbdkk6L_3oge4snTzLw8vAwh14wmTGTsbu-HzkGbHLzDhHIus0yckBnTgseKU3E62c_JRQh7SlORKzUj90v_foAO-uaIEVrbGDCfkbdRj85bf2y6CFwVoevRwPfVuMgNpkUfLsmZhTbg1e-ck-3jw3b5HK83T6vlYh3XWutYSilMpaTIJU8pqxiWMrfALKcK09xkTAAts5KBqTBTVDAJY5SnpWHpCMSc3P7U1tBi0Tjjx18--hqGEIrV60uxUHSsV0Lrf-zm7a-9mdgdQtvvgm-HvvEuTOEXojBn_g</recordid><startdate>20191121</startdate><enddate>20191121</enddate><creator>Chen, Mao-bing</creator><creator>Wang, Hua</creator><creator>Zheng, Qi-han</creator><creator>Zheng, Xu-wen</creator><creator>Fan, Jin-nuo</creator><creator>Ding, Yun-long</creator><creator>Niu, Jia-li</creator><creator>Kim, Seung Up</creator><general>Public Library of Science</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20191121</creationdate><title>Comparative efficacy of tenofovir and entecavir in nucleos</title><author>Chen, Mao-bing ; Wang, Hua ; Zheng, Qi-han ; Zheng, Xu-wen ; Fan, Jin-nuo ; Ding, Yun-long ; Niu, Jia-li ; Kim, Seung Up</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g999-4443cd643842501d1eb48fa1f206e58c713a0b7b1acde760314a13a85bc15e583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antiretroviral agents</topic><topic>Carcinoma</topic><topic>Comparative analysis</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Entecavir</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatocellular carcinoma</topic><topic>Tenofovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Mao-bing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zheng, Qi-han</creatorcontrib><creatorcontrib>Zheng, Xu-wen</creatorcontrib><creatorcontrib>Fan, Jin-nuo</creatorcontrib><creatorcontrib>Ding, Yun-long</creatorcontrib><creatorcontrib>Niu, Jia-li</creatorcontrib><creatorcontrib>Kim, Seung Up</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Mao-bing</au><au>Wang, Hua</au><au>Zheng, Qi-han</au><au>Zheng, Xu-wen</au><au>Fan, Jin-nuo</au><au>Ding, Yun-long</au><au>Niu, Jia-li</au><au>Kim, Seung Up</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative efficacy of tenofovir and entecavir in nucleos</atitle><jtitle>PloS one</jtitle><date>2019-11-21</date><risdate>2019</risdate><volume>14</volume><issue>11</issue><spage>e0224773</spage><pages>e0224773-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B. The Web of Science, PubMed, Cochrane Library, EMBASE, Clinical Trials and China National Knowledge Infrastructure(CNKI) databases were electronically searched to collect randomized controlled trials (RCTs) regarding the comparison between tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) since the date of database inception to July 2019. Two researchers independently screened and evaluated the obtained studies and extracted the outcome indexes. RevMan 5.3 software was used for the meta-analysis. Early on, tenofovir had a greater ability to inhibit the hepatitis B virus, I.sup.2 = 0% [RR = 1.08, 95% CI (1.03, 1.13), P<0.01] (96 weeks). Entecavir can normalize the ALT levels earlier, I.sup.2 = 0% [RR = 0.87, 95% CI (0.77, 0.98), P = 0.02] (48 weeks). However, there was no statistically significant difference between TDF and ETV at 144 weeks. Tenofovir was as effective as entecavir in terms of HBeAg clearance and HBeAg seroconversion, I.sup.2 = 0% [RR = 1.05, 95% CI (0.68, 1.62), P = 0.82]; I.sup.2 = 69% [RR = 0.93, 95% CI (0.54, 1.61), P = 0.80]. The difference in the incidence of elevated creatine kinase levels was not statistically significant I.sup.2 = 0% [RR = 0.66, 95% CI (0.27, 1.60), P = 0.35]. Tenofovir and entecavir were equally effective in the treatment of patients with nucleos(t)ide analogue-naive chronic hepatitis B. In addition, TDF has an advantage in the incidence of hepatocellular carcinoma. Additional RCTs and a large-sample prospective cohort study should be performed.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0224773</doi><tpages>e0224773</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-11, Vol.14 (11), p.e0224773 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_gale_incontextgauss_ISR_A606436399 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Antiretroviral agents Carcinoma Comparative analysis Creatine Creatine kinase Entecavir Hepatitis B Hepatitis B virus Hepatocellular carcinoma Tenofovir |
| title | Comparative efficacy of tenofovir and entecavir in nucleos |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A15%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20efficacy%20of%20tenofovir%20and%20entecavir%20in%20nucleos&rft.jtitle=PloS%20one&rft.au=Chen,%20Mao-bing&rft.date=2019-11-21&rft.volume=14&rft.issue=11&rft.spage=e0224773&rft.pages=e0224773-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0224773&rft_dat=%3Cgale%3EA606436399%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A606436399&rfr_iscdi=true |